Ganymed Pharmaceuticals AG

http://www.ganymed-pharmaceuticals.de

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects. Ganymed's lead program, IMAB362, is in advanced phase II testing for gastroesophageal cancer. IMAB362 binds to the tight junction protein Claudin-18.2 which is expressed in up to 80% gastroesophageal adenocarcinomas, 60% pancreatic tumors as well as in other various solid tumors. Ganymed is also developing IMAB027, a monoclonal antibody targeting GT512 which is absent in healthy adult organs, but is expressed in a wide range of solid cancers, including testicular, ovarian, uterine, and lung cancers. The company plans to initiate clinical studies with IMAB027 in the near future. Ganymed is a private company that was founded in 2001 as a spin-off from the Universities of Mainz and Zurich. Its majority shareholder is ATS Beteiligungsverwaltung GmbH. Other investors include Future Capital AG, MIG Fonds, First Capital Partner GmbH, and private individuals. *

	Start	2001-01-01 established
	Group	Astellas (Group)
	Industry	BIOTECH
	Industry 2	claudiximab (iMAB362/GC182)
	Person	Türeci, Özlem (Ganymed 200811 CEO + CSO)
	Person 2	St-Onge, Luc (Apceth Biopharma 201708 before Ganymed + Affectis CBO + DeveloGen)

	Region	Mainz
	Country	Germany
	Street	12 Freiligrathstr.
	City	55131 Mainz
	Tel	+49-6131-1440-100
		Address record changed: 2018-07-24

Basic data	Employees	C: 51 to 100 (2016-10-28)

		* Document for ï¿½About Sectionï¿½: Ganymed Pharmaceuticals AG. (9/11/13). "Press Release: Ganymed Pharmaceuticals Announces CE Marking for Test to Assess Claudin-18.2 Expression in Solid Tumors". Mechelen.

		Record changed: 2019-06-09

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Advertise

Ganymed Pharmaceuticals AG

More documents for Astellas (Group)